Sandbox2: Difference between revisions
Line 70: | Line 70: | ||
{{familytree/start}} | {{familytree/start}} | ||
{{familytree | | | | | | | | | | | | | A01 | | | A01= <div style="float: left; text-align: left; width: 24em; padding:1em;">''' | {{familytree | | | | | | | | | | | | | A01 | | | A01= <div style="float: left; text-align: left; width: 24em; padding:1em;">'''Initial managment'''<br> | ||
❑ Determine blood pressure <br> | ❑ Determine blood pressure <br> | ||
❑ Determine heart rate <br> | ❑ Determine heart rate <br> | ||
Line 103: | Line 103: | ||
❑ Administration of: | ❑ Administration of: | ||
:❑ [[Ibutilide]] is the prefered treatment, administer 1 mg in an infusion over 10 minutes, if the tachycardia is not controlled give another 1 mg infusion over 10 minutes ([[ACC AHA guidelines classification scheme|class I, level of evidence B)]] | :❑ [[Ibutilide]] is the prefered treatment, administer 1 mg in an infusion over 10 minutes, if the tachycardia is not controlled give another 1 mg infusion over 10 minutes ([[ACC AHA guidelines classification scheme|class I, level of evidence B)]] | ||
<br>''Or''<br><br> | |||
:❑ [[Procainamide]], 20 to 50 mg/minute until the arrythmia is controlled or reach 17 mg/kg. Must monitor blood pressure every 5 to 10 minnutes ([[ACC AHA guidelines classification scheme|class I, level of evidence B)]] | :❑ [[Procainamide]], 20 to 50 mg/minute until the arrythmia is controlled or reach 17 mg/kg. Must monitor blood pressure every 5 to 10 minnutes ([[ACC AHA guidelines classification scheme|class I, level of evidence B)]] | ||
❑ [[Adenosine]] should be used with caution because may produce [[AF]] 6 mg (initial dose) that could be followed by 12 mg if initial dose not effective. Administer IV followed by 10 cc of saline solution<br> | ❑ [[Adenosine]] should be used with caution because may produce [[AF]] 6 mg (initial dose) that could be followed by 12 mg if initial dose not effective. Administer IV followed by 10 cc of saline solution<br> | ||
Line 126: | Line 127: | ||
:❑ [[Procainamide]] administer 20 to 50 mg/minute until the arrythmia is controlled or reach 17 mg/kg. Must monitor blood pressure every 5 to 10 minnutes ([[ACC AHA guidelines classification scheme|class I, level of evidence C]])<br> | :❑ [[Procainamide]] administer 20 to 50 mg/minute until the arrythmia is controlled or reach 17 mg/kg. Must monitor blood pressure every 5 to 10 minnutes ([[ACC AHA guidelines classification scheme|class I, level of evidence C]])<br> | ||
:❑ [[Amiodarone]], administer 5-7 mg/kg over 30-60 minutes (initial dose), then 1.2-1.8 g daily continuous infusion or in divided oral doses until 10 g total ([[ACC AHA guidelines classification scheme|class IIb, level of evidence B]])<br> | :❑ [[Amiodarone]], administer 5-7 mg/kg over 30-60 minutes (initial dose), then 1.2-1.8 g daily continuous infusion or in divided oral doses until 10 g total ([[ACC AHA guidelines classification scheme|class IIb, level of evidence B]])<br> | ||
❑ Avoid AV blocking agents ([[ACC AHA guidelines classification scheme|class III, level of evidence B]])<br> | ❑ Avoid AV blocking agents ([[ACC AHA guidelines classification scheme|class III, level of evidence B]]), such as:<br> | ||
:❑ Digitalis glycosides | |||
:❑ Nondihydropyridine calcium channel antagonists | |||
</div> | | </div> | | ||
C02= <div style="float: left; text-align: left; width: 27em; padding:1em;"> | C02= <div style="float: left; text-align: left; width: 27em; padding:1em;"> | ||
❑ Catheter ablation ([[ACC AHA guidelines classification scheme|class I, level of evidence B]]<br> | |||
❑ Urgent electric [[cardioversion]] ([[ACC AHA guidelines classification scheme|class I, level of evidence B]])<br> | ❑ Urgent electric [[cardioversion]] ([[ACC AHA guidelines classification scheme|class I, level of evidence B]])<br> | ||
</div>}} | </div>}} |
Revision as of 17:08, 19 March 2014
|
Overview
Wolff-Parkinson-White syndrome (WPW) is a syndrome of pre-excitation of the ventricles of the heart due to an accessory pathway known as the Bundle of Kent. The diagnosis is made when a patient with pre-existing WPW patern in the ECG developes an arrythmia which involves an accesory pathway. The treatment is focused on recovering sinus rythm. Atrial Fibrillation in a patient with WPW is lifethretening and should be managed urgently.
Causes
Life Threatening Causes
Life-threatening causes include conditions which result in death or permanent disability within 24 hours if left untreated. Wolff-Parkinson-White syndrome can be a life-threatening condition and must be treated as such irrespective of the underlying cause.
Common Causes
WPW is a congenic disease
Diagnosis
Shown below is an algorithm summarizing the initial aproach to Wolff-Parkinson-White syndrome according to the 2003 ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias.[1]
AVRT: AV reentrant tachycardia
Characterize the symptoms:
Characterize the timing of the symptoms: | |||||||||||||||||||||||||||||||||||||||||||
Identify possible triggers: | |||||||||||||||||||||||||||||||||||||||||||
❑ Examine the patient
❑ Order and monitor the ECG | |||||||||||||||||||||||||||||||||||||||||||
Orthodromic AVRT The impulse travels from the atrium to the ventricle through the AV node and returns to the atrium through the accesory pathway. 90-95% of WPW ❑ Narrow QRS complexes | Antidromic AVRT The impulse travels from the atrium to the ventricle through theaccesory pathway and from the ventricle to the atrium through the AV node. Less than 10% of WPW ❑ Wide QRS complexes | ||||||||||||||||||||||||||||||||||||||||||
Managment
Shown below is an algorithm summarizing the initial aproach to Wolff-Parkinson-White syndrome according to the 2003 ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias.[1]
Initial managment ❑ Determine blood pressure | |||||||||||||||||||||||||||||||||||||||||||||||
Stable patient | Unstable patient | ||||||||||||||||||||||||||||||||||||||||||||||
❑ Assess the ECG |
| ||||||||||||||||||||||||||||||||||||||||||||||
Orthodromic AVRT | Antidromic AVRT | ||||||||||||||||||||||||||||||||||||||||||||||
Treatment. ❑ Use Vagal maneuvers (class I, level of evidence B)
| Treatment. ❑ Administration of:
❑ Adenosine should be used with caution because may produce AF 6 mg (initial dose) that could be followed by 12 mg if initial dose not effective. Administer IV followed by 10 cc of saline solution | ||||||||||||||||||||||||||||||||||||||||||||||
Wolff-Parkinson-White syndrome with Atrial fibrillation
Shown below is an algorithm summarizing the managment of Wolff-Parkinson-White syndromewith Atrial fibrillation according to the ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation.[2]
❑ Control ventricular response | |||||||||||||||||||||||||||||||||||||||||
Stable patient | Unstable patient | ||||||||||||||||||||||||||||||||||||||||
❑ Restore sinus rythm (class I, level of evidence C)
❑ Avoid AV blocking agents (class III, level of evidence B), such as:
| ❑ Catheter ablation (class I, level of evidence B | ||||||||||||||||||||||||||||||||||||||||
References
- ↑ 1.0 1.1 "ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias—Executive Summary". Retrieved 15 August 2013.
- ↑ Fuster, V.; Rydén, LE.; Cannom, DS.; Crijns, HJ.; Curtis, AB.; Ellenbogen, KA.; Halperin, JL.; Le Heuzey, JY.; Kay, GN. (2006). "ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society". Circulation. 114 (7): e257–354. doi:10.1161/CIRCULATIONAHA.106.177292. PMID 16908781. Unknown parameter
|month=
ignored (help)